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Abstract Nur77 and Nurr1 are critical for proopiomelanocor-
tin (POMC) regulation by corticotrophin releasing hormone
(CRH) in corticotrophs. We analyze the regulation and activity
of Nur77 by interleukin (IL)-1 in AtT-20 corticotrophic cells
and its consequences on POMC regulation. IL-1 induces
Nur77 and not Nurr1 mRNA and shows an increased transcrip-
tional activity on the NurRE site, an e¡ect dependent of p38
protein kinase activity. A NurRE mutation abrogates POMC
promoter transcription by IL-1 and a stable AtT-20 clone over-
expressing a dominant negative form of Nur77 is unresponsive
to IL-1-dependent POMC induction and adrenocorticotrophin
(ACTH) secretion. These results demonstrate that Nur77 is
essential for POMC stimulation by IL-1 in corticotrophs.
3 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Interleukin-1 (IL-1), among other cytokines, is critically in-
volved in the in£ammatory process, and has been shown to
a¡ect hormone secretion, acting at di¡erent levels of the hy-
pothalamic pituitary adrenal (HPA) axis [1,2]. IL-1 binding
sites and receptors have been characterized both in hypotha-
lamic and pituitary glands [3] and in the corticotrophic AtT-
20 cell line [4].
IL-1 stimulates the secretion of adrenocorticotrophin
(ACTH) and L-endorphin, and induces proopiomelanocortin
(POMC) mRNA expression in the pituitary in vivo and in
vitro [5,6]. Chronic infusion of IL-1 results in a persistent
elevation of ACTH and POMC levels in rats [5,7], and IL-
1L stimulates ACTH secretion from human pituitary Cushing
tumors in vitro [8]. IL-1L, IL-6, and tumor necrosis factor-K
stimulate the POMC promoter and potentiate the stimulatory
e¡ect of corticotrophin releasing hormone (CRH) in AtT-20
cells [9]. CRH pretreatment of rats sensitizes the pituitary to
IL-1-dependent ACTH secretion [10] possible due to an incre-
ment in IL-1 receptor density [11] and IL-1 potentiates L-en-
dorphin secretion stimulated by CRH [12].
Nur77 and Nurr1 are nuclear proteins that belong to the
orphan receptor family, and play an important role in POMC
induction by CRH. Two major recognition sites have been
described in the POMC promoter, the NBRE site located
within the nGRE site that binds one of these factors as a
monomer [13], and the NurRE site, located at 3404 bp
from the transcription start site, that can bind these proteins
as homodimers or heterodimers [14,15]. The NurRE site was
proved to be more relevant for POMC promoter induction by
CRH [14]. The third member of the Nurr1 subfamily (NOR1)
is less relevant in stimulating the POMC promoter [15].
Stimulation by the gp130-dependent cytokines IL-6, leuke-
mia inhibitory factor (LIF) and IL-11 of ACTH secretion and
POMC mRNA expression was also proved [1,2]. In addition,
IL-1 stimulates LIF mRNA levels in AtT-20 cells [16]. This
implicates that IL-1 may also be part of the auto/paracrine
modulation of the pituitary exerted by local production of
LIF and IL-6 [1,2].
Further knowledge of IL-6, LIF and IL-11 transduction
pathways involved in POMC promoter activation has been
gained recently and involves the STAT pathway [17,18]. LIF
and IL-11 stimulate the intracellular levels of the inhibitor of
cytokine action SOCS-3 and stable overexpression of this pro-
tein inhibits ACTH release by these cytokines [19]. Although
the signal transduction pathways triggered by the IL-1 recep-
tor have been widely studied [20,21], there have not been
advances on the transcription factors involved in IL-1 induc-
tion of POMC mRNA.
In this report we analyze the molecular events involved in
IL-1 induction of the POMC promoter, analyzing Nur77 and
Nurr1 induction and activity.
2. Materials and methods
2.1. Cell culture and stimulation
AtT-20 cells, obtained from the American Type Culture Collection
(Rockville, MD, USA), were cultured in Dulbecco’s modi¢ed Eagle’s
medium (DMEM), 10% fetal calf serum (FCS) with glutamine and
antibiotics. Cells were treated as indicated for each experiment with
human/rat CRH (Bachem, Heidelberg, Germany), IL-1, IL-6 (Roche
Molecular Biochemicals, Mannheim, Germany), LIF or IL-11 (RyD
system, Inc., Minneapolis, MN, USA). When used, the inhibitors of
protein kinases, bisindolylmaleimide-1 and SB203580 (Calbiochem,
San Diego, CA, USA) were added 15 min before other stimulatory
treatment.
2.2. Northern blot
AtT-20 cells were plated on six-well plates and 24 h later stimulated
in serum-free DMEM. RNA was isolated by the guanidine isothio-
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cyanate followed by the phenol-chloroform method [22]. RNA extrac-
tion, denaturing gel electrophoresis, Northern blotting, preparation of
radiolabeled probes, and hybridization procedures were performed as
described previously [22]. For detection of Nur77 mRNA a PvuII
fragment of 1.4 kb from Nur77 cDNA was used [14,23]. For detection
of Nurr1 mRNA a HindIII/PstI fragment of 500 bp was used [24].
A 1-kb PstI cDNA was used as actin probe [25]. The cDNA probes
were labeled with a random-primed kit with [K-32P]deoxycytidine tri-
phosphate (dCTP) (Amersham, Buckinghamshire, England, UK).
POMC cRNA [26] probe was generated by in vitro transcription using
the T3 RNA polymerase in the presence of [K32P]uridine triphosphate
(UTP).
2.3. Transient transfection and reporter luciferase, chloramphenicol
acetyl transferase (CAT) and L-galactidase (gal) assays
AtT-20 cells were plated on six-well plates and transfected with
lipofectamine (Invitrogen, Frederik, MD, USA) as previously de-
scribed [27] with 500 ng of the reporter plasmids NurRE-luciferase
(LUC), NBRE-LUC (that contain three copies of NurRE or NBRE
sites coupled to the minimal POMC (334/+63) promoter respec-
tively), POMC-LUC, POMC(NurREmut)-LUC [14,23], (3480,
3336, 3281, 3163) Nur77 promoter coupled to the CAT gene
(Nur77-CAT) [28] or KB-LUC [29], in conjunction with a control
RSV-Lgal construction (200 ng). After overnight washout, cells were
stimulated for 2 or 6 h in serum-free DMEM as indicated. LUC, CAT
and L-gal activities were measured as previously described [27]. Re-
sults were standardized for L-gal activity.
2.4. Stable transfection
48 h after transfection with the Nur77 dominant negative
(pHbNur77ZnCT) expression vector [30], and selection with geneticin
antibiotic (300 mg/ml) (Invitrogen, Frederik, MD, USA) for 3 weeks,
constitutive expression of the dominant negative Nur77 form was
tested by Northern blot using the Nur77 fragment as probe.
2.5. Hormone determination
ACTH was determined by radioimmunoassay (RIA) as we previ-
ously described [31].
2.6. Statistical analysis
Statistics were performed using one-factor analysis of variance
(ANOVA) in combination with the Sche¡e’s test. Results are ex-
pressed as meansQS.E.M.
3. Results
3.1. Activation and induction of Nur77 by IL-1
IL-1 but not other cytokines that stimulate POMC/ACTH
[1,2,5,6,9,18,19], such as IL-6, IL-11 or LIF, stimulates tran-
scription of a construct containing only the POMC NurRE
site (NurRE-LUC) (Fig. 1A). This e¡ect is speci¢c for the
NurRE site, whereas the NBRE site does not respond to
IL-1, but responds, as described [14] to CRH treatment
(Fig. 1B).
In correlation with an increased transcription at the NurRE
site, IL-1 induces Nur77 mRNA at 1 h returning to basal at
2 h (Fig. 1C). Contrarily, no induction of Nurr1 mRNA was
detected at any time (Fig. 1C). This stimulatory e¡ect is due
to an increase in Nur77 transcription as (3480, 3336 and
3281) Nur77 promoter constructs are also stimulated by IL-
1. Contrarily, the 3163 construct is unresponsive to IL-1
stimulation showing that the 3281^163 fragment confers IL-
1 sensitivity (Fig. 1D).
The stimulatory e¡ects of IL-1 on NurRE-dependent tran-
scription and Nur77 mRNA induction are blocked by
SB203580, a speci¢c inhibitor of p38, and not by bisindolyl-
maleimide, a speci¢c inhibitor of protein kinase C (PKC) (Fig.
2A and B). This implicates p38 activation as essential for IL-1
stimulation.
3.2. IL-1 and CRH synergize on Nur77 activity
The enhancement of POMC induction [9] and ACTH se-
cretion [12,32] by CRH, induced by IL-1 pretreatment (Fig.
3B) is observed also on Nur77 activity (Fig. 3A).
Fig. 1. IL-1 stimulates Nur77 and NurRE activity in AtT-20 cells.
Relative activity of NurRE-LUC (A) or NBRE-LUC (B) in trans-
fected AtT-20 cells under IL-1 (100 U/ml), IL-6 (2000 U/ml), LIF
(20 ng/ml), IL-11 (10 ng/ml), or CRH (100 nM) stimulation. Means
QS.E.M. of four independent experiments (n=3 each, *P6 0.001
with respect to corresponding basal levels). C: Northern blot analy-
sis of AtT-20 cells stimulated at the indicated times with IL-1 (100
U/ml). One representative out of three independent experiments
with similar results. D: Relative activity of 3480, 3336, 3281 and
3163 promoter Nur77-CAT constructs in transfected AtT-20 cells
unstimulated (white bars) or stimulated for 1 h with IL-1 (100 U/
ml) (black bars). MeansQS.E.M. of two independent experiments
(n=3 each, *P6 0.001 with respect to the corresponding basal lev-
els).
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3.3. The NurRE site is essential for POMC transcription by
IL-1 stimulation
POMC stimulation by IL-1 depends on the NurRE site, as
a construct with a mutation on NurRE (POMC(NurREmut)-
LUC) that does not bind Nur77 [14] is not stimulated by IL-1,
contrarily to the wild-type POMC-LUC construct (Fig. 4).
3.4. The AtT20N77 cell line is unresponsive to NurRE-
dependent transcription, POMC mRNA induction and
ACTH secretion by IL-1
As an additional approach for the signi¢cance of the
NurRE site for POMC transcription, we generated and func-
tionally checked a stable transfected cell line that constitu-
tively expresses a dominant negative form of the Nur77 pro-
tein [30], denominated AtT20N77 (Fig. 5A). AtT20N77 cells
are less responsive (5- vs. 25-fold) to CRH stimulation and do
not respond to IL-1 stimulation of NurRE-LUC (Fig. 5B).
This e¡ect is speci¢c for Nur77 activity as both AtT20N77
and AtT-20 cells increase nuclear factor (NF)-UB activity to
similar levels as by IL-1 stimulation (data not shown).
Contrarily to IL-1 stimulation of POMC mRNA levels and
Fig. 2. p38 activity mediates IL-1 stimulation of Nur77. Relative ac-
tivity of NurRE-LUC in transfected AtT-20 cells (A) or Northern
blot analysis of AtT-20 cells (B) stimulated with IL-1 (100 U/ml),
IL-1+bisindolylmaleimide-1 (BSM-1) (10 mM) or IL-1+SB203580
(SB) (10 mM). A: MeansQS.E.M. of three independent experiments
(n=3 each, *P6 0.001 with respect to basal levels; **P6 0.001 with
respect to IL-1 levels). B: One representative out of three indepen-
dent experiments is shown.
Fig. 3. IL-1 increases CRH induction of NurRE activation. Relative
activity of NurRE-LUC in transfected AtT-20 cells (A) or ACTH
secretion in AtT-20 cells (B), after 16 h pretreatment with IL-1 (100
U/ml), washout, and further 6 h (A) or 1 h (B) stimulation with
CRH (100 nM). A: MeansQS.E.M. of two independent experiments
(n=3 each, *P6 0.05 with respect to CRH levels). B: One represen-
tative, out of three independent experiments (n=4 each, *P6 0.05
with respect to CRH treatment).
Fig. 4. NurRE confers IL-1 stimulation of POMC promoter. Rela-
tive activity of POMC-LUC or POMC(NurREmut)-LUC in trans-
fected AtT-20 cells, stimulated 2 h with IL-1 (100 U/ml), as indi-
cated. MeansQS.E.M. of two independent experiments (n=3 each,
*P6 0.01 with respect to basal levels).
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ACTH secretion in AtT-20 cells [6], IL-1 is unable to stimu-
late AtT20N77 cells (Fig. 5C and D).
4. Discussion
Recently, the molecular pathways involved in CRH induc-
tion of POMC mRNA were clari¢ed, and involve the orphan
receptor subfamily proteins Nur77, Nurr1 and NOR1 [13^
15,23].
In this paper we demonstrate that IL-1 e¡ects on POMC
mRNA induction involve also Nur77 (but not Nurr1) induc-
tion and activity. Stimulation at the NurRE site by IL-1 is
dependent on p38 protein kinase activity. We demonstrate
that Nur77 is essential for the function of IL-1 in corticotroph
cells: (a) the POMC promoter with the mutated NurRE site is
unresponsible to IL-1 stimulation and (b) the induction of
POMC mRNA, stimulation of ACTH secretion and increased
transcriptional activity at the NurRE site are blocked in
AtT20N77 cells, which express a Nur77 dominant negative
form. The functional relevance of Nur77 induction by IL-1
is underlined by the fact that the IL-1^CRH synergism on
ACTH secretion correlates with the synergism in Nur77 tran-
scriptional activity.
The insensitivity of the NBRE site to IL-1 correlates with a
preponderant role of NurRE to CRH stimulation of POMC
[14] and may be a consequence of di¡erent responsiveness of
each site, as CRH produces a 20-fold increase in NurRE-
LUC, and only a 2-fold increase in NBRE-LUC [14].
IL-1 stimulates Nur77 and not Nurr1 mRNA. Nur77 ho-
modimeric binding may be involved in NurRE-dependent ac-
tivation by IL-1 treatment, although we can not rule out
possible heterodimeric formation among Nur77 and NOR1
or preexisting Nurr1 protein. The strict dependence of
Nur77 is also con¢rmed, as overexpression of a dominant
negative form in a stable transfected cell line abolishes
NurRE-dependent transcription, POMC mRNA induction
and ACTH secretion to IL-1 treatment.
Mutual modulatory action of CRH and IL-1 at the pitui-
tary for control of L-endorphin and ACTH secretion was
described. CRH and IL-1 produce a higher increase in L-en-
dorphin and ACTH secretion with respect to CRH alone
[9^12].
IL-1 has been shown to modulate CRH receptors in the
pituitary [5] and CRH treatment a¡ects IL-1 sensitivity of
pituitary in vivo [10] and in vitro [11]. We demonstrate that
IL-1 and CRH synergize to increase transcription at the
NurRE site, this e¡ect provides a molecular basis for the
synergism between IL-1 and CRH on ACTH secretion and
POMC mRNA induction.
IL-1 stimulation triggers di¡erent signal transduction path-
ways (PKC, JunK and p38 protein kinase pathways, among
others) upon interaction of the IL-1 receptor with accessory
proteins such as the IL-1 receptor accessory protein (IL-
1RAcP) and TRAF proteins [20]. We show that the p38 pro-
tein kinase but not the PKC activity is necessary for NurRE-
dependent transcription. Contrarily, the inhibitory e¡ect of
p38 on Nur77 mRNA was less marked, implicating that
some other signal is involved in Nur77 mRNA increase. Di-
rect stimulation of Nur77 transcriptional activity by p38 can-
not been ruled out. In concordance, several phosphorylation
sites, present in the Nur77 protein, may be the target for p38
regulation. IL-1 treatment of AtT-20 cells stimulates the phos-
Fig. 5. Nur77 is essential for POMC mRNA induction and in-
creased ACTH secretion by IL-1. A: Northern blot analysis of the
AtT20N77 clone under basal and CRH (100 nM)-stimulated condi-
tion for detection of constitutive dominant negative Nur77 expres-
sion (Nur77 DN). B: Relative activity of NurRE-LUC in trans-
fected AtT-20 and AtT20N77 cells under IL-1 (100 U/ml) or CRH
(100 nM) stimulation. MeansQS.E.M. of three independent experi-
ments (n=3 each, *P6 0.001 with respect to the corresponding
basal levels, **P6 0.001 with respect to CRH-stimulated AtT-20
cells). Northern blot analysis (C) or ACTH secretion (D) of AtT-20
and AtT20N77 cells stimulated for 18 h with IL-1 (100 U/ml).
C: One representative out of three independent Northern blots is
shown. D: One representative out of two independent experiments
(n=4 each, *P6 0.01 with respect to basal levels).
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phorylation of a protein with the same molecular weight than
Nur77 [32]. Further studies are required to identify whether
p38 modulation is exerted by direct phosphorylation of Nur77
as is the direct phosphorylation of Nur77 by extracellular
signal-regulated kinase (ERK)2 [27].
This work unravels for the ¢rst time the molecular path-
ways involved in pituitary POMC mRNA induction and
ACTH-stimulated secretion by IL-1, and demonstrates a strict
Nur77 dependence for IL-1 e¡ects in corticotrophic cells.
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